**RATIONALE FOR CIT COMBINATION AND STUDY DESIGN**

Monotherapy in subsets of patients,3-6 proof-of-concept clinical data1,2 PD-L1/PD-1 inhibitors act largely by re-invigorating pre-existing anti-tumor T-cell responses and are most effective in inflamed immune-excluded TME13-16

**MORPHEUS-PDAC**

The primary endpoint of both studies was:

- CIT combinations may generate durable anti-tumor responses in larger subsets of patients by targeting multiple immune-evasion strategies.
- Overall survival (OS)

**Standard of Care for Patients With PDAC**

Metastatic sites at enrollment, n

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Metastatic sites</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>(control)</td>
<td>pancreas</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>lung</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>liver</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>other</td>
<td>1</td>
</tr>
<tr>
<td>(experimental arm)</td>
<td>pancreas</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>lung</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>liver</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>other</td>
<td>8</td>
</tr>
</tbody>
</table>

**Demographic and disease characteristics**

- Baseline NLR ≥ 5
- Baseline CRP level > 1.2 mg/dL

**Efficacy**

- ORR: 0%
- CR: 0%
- PD: 0%
- PR: 0%

**Safety**

- Related AE leading to dose modification/interruption: 4 (30.8) 6 (50.0)
- Grade 5 AE: 1 (6.7) 3 (20.0)
- Treatment-related death: 1 (6.7%)
- One patient withdrew before the first treatment infusion due to an AE, and 1 patient withdrew from the study due to progressive disease.

**CONCLUSIONS FOR MORPHEUS-PDAC AND MORPHEUS-GC**

In MORPHEUS-PDAC, no associations were seen between any of the biomarkers evaluated and disease response, but the finding needs to be replicated in a larger patient population. In MORPHEUS-GC, a positive correlation was found between PD-L1 tumor cell (TC) and intratumoral stroma CD8 (ITS2 + ITS3 %) and OS. This positive correlation was not seen in MORPHEUS-PDAC.

**ACKNOWLEDGMENTS**

This study is sponsored by F. Hoffmann-La Roche, Ltd. The authors thank all of the patients who participated in this study. The authors also thank all of the investigators and study staff for their efforts. This study was conducted in accordance with the Declaration of Helsinki and all applicable regulatory requirements. The safety data for MORPHEUS-GC are summarized in Table 5 and the additional content (see QR code).

**REFERENCES**


**DISCLOSURES**

Copies of this poster obtained through Quick Response (QR) Code are available at https://www.asco.org/eventseo/abstract-712.